



Update Summary

Entity name

AUSTRALIAN CLINICAL LABS LIMITED

Security on which the Distribution will be paid

ACL - ORDINARY FULLY PAID

Announcement Type

Update to previous announcement

Date of this announcement

28/3/2023

Reason for the Update

To note the suspension of the DRP in respect of this dividend.

Refer to below for full details of the announcement



Announcement Details

Part 1 - Entity and announcement details

1.1 Name of +Entity

AUSTRALIAN CLINICAL LABS LIMITED

1.2 Registered Number Type

ABN

Registration Number

94645711128

1.3 ASX issuer code

ACL

1.4 The announcement is

☒ Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

To note the suspension of the DRP in respect of this dividend.

1.4b Date of previous announcement(s) to this update

20/2/2023

1.5 Date of this announcement

28/3/2023

1.6 ASX +Security Code

ACL

ASX +Security Description

ORDINARY FULLY PAID

Part 2A - All dividends/distributions basic details

2A.1 Type of dividend/distribution

☒ Ordinary

2A.2 The Dividend/distribution:

relates to a period of six months

2A.3 The dividend/distribution relates to the financial reporting or payment period ending ended/ending (date)

31/12/2022



2A.4 +Record Date

28/3/2023

2A.5 Ex Date

27/3/2023

2A.6 Payment Date

26/4/2023

2A.7 Are any of the below approvals required for the dividend/distribution before business day 0 of the timetable?

- Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity required before business day 0 of the timetable for the dividend/distribution.

☒ No

2A.8 Currency in which the dividend/distribution is made ("primary currency")

AUD - Australian Dollar

2A.9 Total dividend/distribution payment amount per +security (in primary currency) for all dividends/distributions notified in this form

AUD 0.07000000

2A.10 Does the entity have arrangements relating to the currency in which the dividend/distribution is paid to securityholders that it wishes to disclose to the market?

☒ No

2A.11 Does the entity have a securities plan for dividends/distributions on this +security?

☒ We have a Dividend/Distribution Reinvestment Plan (DRP)

2A.11a If the +entity has a DRP, is the DRP applicable to this dividend/distribution?

☒ Yes

2A.11a(i) DRP Status in respect of this dividend/distribution

Full DRP

2A.12 Does the +entity have tax component information apart from franking?

☒ No

Part 3A - Ordinary dividend/distribution

3A.1 Is the ordinary dividend/distribution estimated at this time?

☒ No

3A.1a Ordinary dividend/distribution estimated amount per +security

AUD

**3A.1b Ordinary Dividend/distribution amount per security**

AUD 0.07000000

3A.2 Is the ordinary dividend/distribution franked?☒ Yes**3A.2a Is the ordinary dividend/distribution fully franked?**☒ Yes**3A.3 Percentage of ordinary dividend/distribution that is franked**

100.0000 %

3A.3a Applicable corporate tax rate for franking credit (%)

30.0000 %

3A.4 Ordinary dividend/distribution franked amount per +security

AUD 0.07000000

3A.5 Percentage amount of dividend which is unfranked

0.0000 %

3A.6 Ordinary dividend/distribution unfranked amount per +security excluding conduit foreign income amount

AUD 0.00000000

3A.7 Ordinary dividend/distribution conduit foreign income amount per security

AUD 0.00000000

Part 4A - +Dividend reinvestment plan (DRP)

4A.1 What is the default option if +security holders do not indicate whether they want to participate in the DRP?☒ Do not participate in DRP (i.e. cash payment)**4A.2 Last date and time for lodgement of election notices to share registry under DRP**

Wednesday March 29, 2023 17:00:00

4A.3 DRP discount rate

0.0000 %

4A.4 Period of calculation of reinvestment price**Start Date**

31/3/2023

End Date

6/4/2023

4A.5 DRP price calculation methodology

Average Market Price (being the daily volume weighted average price (calculated to the nearest cent) of shares traded on ASX) for the 5 Trading Days commencing on the third Business Day after the applicable Dividend Record Date (as all those terms are more fully defined in the DRP Plan Rules)

4A.6 DRP Price (including any discount):

AUD

4A.7 DRP +securities +issue date**4A.8 Will DRP +securities be a new issue?**☒ No**4A.9 Is there a minimum dollar amount or number of +securities required for DRP participation?**☒ No**4A.10 Is there a maximum dollar amount or number of +securities required for DRP participation?**☒ No



4A.11 Are there any other conditions applying to DRP participation?

☑ Yes

4A.11a Conditions for DRP participation

Shareholders must be Eligible to participate as that term is defined in the DRP Plan Rules. Participation is optional and voluntary and is not transferable. Participation may be varied or terminated in accordance with the DRP Plan Rules including at the absolute discretion of the Board of Directors of ACL.

4A.12 Link to a copy of the DRP plan rules

<https://investors.clinicallabs.com.au/investor-information/dividends/dividendreinvestmentplan/>

4A.13 Further information about the DRP

Part 5 - Further information

5.1 Please provide any further information applicable to this dividend/distribution

On 27 March 2023, ACL announced to ASX that it was suspending the DRP until further notice and that the DRP will not operate in respect of this dividend. Further information can be found in that announcement.

5.2 Additional information for inclusion in the Announcement Summary